Erasmo M Lopez

US Patent:

20140017283, Jan 16, 2014

Filed:

Jul 11, 2013

Appl. No.:

13/939969

Inventors:

Jaime Paden - Columbia MD, US
Scott A. Maxson - Columbia MD, US
Alla Danilkovitch - Columbia MD, US
Erasmo Lopez - Somerville NJ, US
Samson Tom - Basking Ridge NJ, US

International Classification:

A61K 35/32

US Classification:

424400, 424548, 424 937

Abstract:

This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

US Patent:

20140017292, Jan 16, 2014

Filed:

Jul 11, 2013

Appl. No.:

13/939991

Inventors:

Jaime Paden - Columbia MD, US
Scott A. Maxson - Columbia MD, US
Alla Danilkovitch - Columbia MD, US
Erasmo Lopez - Somerville NJ, US
Samson Tom - Basking Ridge NJ, US

International Classification:

A61L 27/56
A61L 27/36

US Classification:

424423, 424 937

Abstract:

This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

US Patent:

20140030309, Jan 30, 2014

Filed:

Jul 11, 2013

Appl. No.:

13/939981

Inventors:

Jaime Paden - Columbia MD, US
Scott A. Maxson - Columbia MD, US
Alla Danilkovitch - Columbia MD, US
Erasmo Lopez - Somerville NJ, US
Samson Tom - Basking Ridge NJ, US

Assignee:

Osiris Therapeutics, Inc. - Columbia MD

International Classification:

A61L 27/36
A61L 27/50

US Classification:

424423, 424 937, 514 172

Abstract:

This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

US Patent:

20220331485, Oct 20, 2022

Filed:

Jun 30, 2022

Appl. No.:

17/854688

Inventors:

- Columbia MD, US
Jaime Paden - Columbia MD, US
Scott A. Maxson - Columbia MD, US
Alla Danilkovitch - Columbia MD, US
Erasmo Lopez - Somerville NJ, US
Samson Tom - Basking Ridge NJ, US

International Classification:

A61L 27/36
A61K 35/32
A61L 27/24
A61L 27/38
A61L 27/54
A61K 38/01
A61L 27/56
A61L 27/50

Abstract:

A cryopreserved cartilage product is disclosed. The cryopreserved cartilage product can include a partially digested cryopreserved natural cartilage collagen matrix isolated from a subject. The collagen matrix can include viable cells embedded within the collagen matrix that are native to the collagen matrix and that were embedded in the collagen matrix when the collagen matrix was isolated from the subject, at least 70% of the embedded cells native to the collagen matrix can be viable in the cryopreserved cartilage product, and the partially digested collagen matrix can retain interaction between the collagen matrix and the native cells.

US Patent:

20220184277, Jun 16, 2022

Filed:

Feb 25, 2022

Appl. No.:

17/681064

Inventors:

- Columbia MD, US
Jaime PADEN - Columbia MD, US
Scott A. MAXSON - Columbia MD, US
Alla DANILKOVITCH - Columbia MD, US
Erasmo LOPEZ - Somerville NJ, US
Samson TOM - Basking Ridge NJ, US

International Classification:

A61L 27/36
A61K 35/32
A61L 27/24
A61L 27/38
A61L 27/54
A61K 38/01
A61L 27/56
A61L 27/50

Abstract:

This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

US Patent:

20150140057, May 21, 2015

Filed:

Aug 20, 2014

Appl. No.:

14/464123

Inventors:

- Columbia MD, US
Jaime Paden - Columbia MD, US
Scott A. Maxson - Columbia MD, US
Alla Danilkovitch - Columbia MD, US
Erasmo Lopez - Somerville NJ, US
Samson Tom - Basking Ridge NJ, US

International Classification:

A61L 27/36
A61L 27/56
A61L 27/54
A61L 27/38

US Classification:

424422, 424548, 424 937

Abstract:

This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

US Patent:

20150017222, Jan 15, 2015

Filed:

Sep 26, 2014

Appl. No.:

14/498394

Inventors:

- Columbia MD, US
Jaime Paden - Columbia MD, US
Scott A. Maxson - Columbia MD, US
Alla Danilkovitch - Columbia MD, US
Erasmo Lopez - Somerville NJ, US
Samson Tom - Basking Ridge NJ, US

International Classification:

A61L 27/36
A61L 27/54
A61L 27/56
A61L 27/24

US Classification:

424423, 424 937, 514 172

Abstract:

This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

US Patent:

20150004211, Jan 1, 2015

Filed:

Sep 12, 2014

Appl. No.:

14/485210

Inventors:

- Columbia MD, US
Jaime Paden - Columbia MD, US
Scott A. Maxson - Columbia MD, US
Alla Danilkovitch - Columbia MD, US
Erasmo Lopez - Somerville NJ, US
Samson Tom - Basking Ridge NJ, US

International Classification:

A61K 35/32

US Classification:

424423, 424 937

Abstract:

This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.